CMPS.US Compass Pathways Plc

Healthcare Health Care Providers & Services USA Stocks
9.01 USD
Close of Nov 14, 2026
4.88 15.87
Market cap
USD 1.28B
P/E
-
P/B
9.10x
ROE
-161.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is CMPS.US undervalued?

Graham number

The Graham number of Compass Pathways Plc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Compass Pathways Plc fundamental analysis

No fundamental analysis for Compass Pathways Plc yet.

Compass Pathways Plc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Compass Pathways Plc

COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in Augu…

Full company profile